News articles about Avinger (NASDAQ:AVGR) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Avinger earned a daily sentiment score of 0.09 on Accern’s scale. Accern also assigned media headlines about the medical device company an impact score of 47.1493276779865 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment Analysis’s scoring:Get Avinger alerts: Avinger, Inc. (NasdaqCM:AVGR) Return on Assets in Focus & Quant Signal Update (derbynewsjournal.com) Avinger named DAR Good Citizen (thetandd.com) Varying Three Stocks: VIVUS, Inc. (NASDAQ:VVUS), Quorum Health Corporation (NYSE:QHC), Avinger, Inc. (NASDAQ … (thestreetpoint.com) Wobbling Three Stocks: Atlantic Power Corporation (NYSE:AT), Avinger, Inc. (NASDAQ:AVGR), VolitionRx Limited … (thestreetpoint.com) Aviger’s arm lifts Holly Hill Academy, forces Saturday game for title (thetandd.com)
Separately, Ladenburg Thalmann initiated coverage on Avinger in a research report on Friday, March 9th. They set a “buy” rating on the stock.
NASDAQ AVGR remained flat at $$1.32 during trading hours on Friday. The company had a trading volume of 447,253 shares, compared to its average volume of 1,194,553. Avinger has a one year low of $0.95 and a one year high of $38.40. The stock has a market cap of $7.34 million, a PE ratio of -0.02 and a beta of 0.55.
Avinger (NASDAQ:AVGR) last issued its quarterly earnings data on Monday, May 14th. The medical device company reported ($5.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($4.53). The company had revenue of $1.81 million during the quarter. equities analysts predict that Avinger will post -1.93 EPS for the current year.
Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.